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Adiponectin is a hormone that lowers glucose produc-
tion by increasing liver insulin sensitivity. Insulin
blocks the generation of biochemical intermediates for
glucose production by inhibiting autophagy. However,
autophagy is stimulated by an essential mediator of adi-
ponectin action, AMPK. This deadlock led to our hy-
pothesis that adiponectin inhibits autophagy through a
novel mediator. Mass spectrometry revealed a novel
protein that we call suppressor of glucose by autoph-
agy (SOGA) in adiponectin-treated hepatoma cells.
Adiponectin increased SOGA in hepatocytes, and
siRNA knockdown of SOGA blocked adiponectin inhi-
bition of glucose production. Furthermore, knock-
down of SOGA increased late autophagosome and ly-
sosome staining and the secretion of valine, an amino
acid that cannot be synthesized or metabolized by
liver cells, suggesting that SOGA inhibits autophagy.
SOGA decreased in response to AICAR, an activator of
AMPK, and LY294002, an inhibitor of the insulin sig-
naling intermediate, PI3K. AICAR reduction of SOGA
was blocked by adiponectin; however, adiponectin
did not increase SOGA during PI3K inhibition, sug-
gesting that adiponectin increases SOGA through the
insulin signaling pathway. SOGA contains an internal
signal peptide that enables the secretion of a circulating
fragment of SOGA, providing a surrogate marker for
intracellular SOGA levels. Circulating SOGA increased in
parallel with adiponectin and insulin activity in both
humans and mice. These results suggest that adiponectin-
mediated increases in SOGA contribute to the inhibition
of glucose production. (Am J Pathol 2010, 177:1936–1945;
DOI: 10.2353/ajpath.2010.100363)
Adipose tissue exerts a powerful effect on glucose me-
tabolism by regulating the concentration of circulating
adiponectin.1 High adiponectin in the lean state is linked
to elevated insulin sensitivity, whereas low adiponectin in
the obese state is linked to insulin resistance and type II
diabetes.2–5 Endogenous glucose production is elevated
in both type I and type II diabetes.6 Studies in mice and
liver cells show that adiponectin lowers glucose produc-
tion by increasing the insulin sensitivity of the liver.7–9
The adiponectin signaling pathway is currently linked
to i) adiponectin receptors that bind to full-length adi-
ponectin or the carboxy-terminal ‘globular’ fragment of
adiponectin, ii) the intracellular domains of adiponectin
receptors 1 and 2 binding to the adaptor APPL1, and iii)
the activation of AMPK, a signaling intermediate that
reduces the gene expression of rate-limiting enzymes for
glucose production.8–20 However, the inhibition of glu-
cose production by this pathway is not completely clear.
Glucose production depends on autophagy, a regu-
lated mechanism of intracellular degradation that is in-
hibited by insulin. The reduction of insulin during fasting,
starvation, and type I diabetes increases autophagy in
the liver. 21–23 Autophagy provides the biochemical inter-
mediates for glucose production through the hydrolysis
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of proteins, glycogen, and triglycerides.24–26 Insulin inhi-
bition of autophagy in isolated hepatocytes is linked to
the activation of mTOR.27,28 Hence, we were perplexed
by reports that AMPK, an essential mediator of adiponec-
tin action, inhibits mTOR and stimulates autophagy.29–35
Mass spectrometry analysis of adiponectin-treated hep-
atoma cells revealed a protein that we call suppressor of
glucose by autophagy (SOGA). Our initial interest in SOGA
was based on conserved domains, which predicted that
SOGA could participate in the regulation of autophagy.36
The results presented here indicate that the regulation and
function of SOGA can explain how adiponectin enhances
insulin inhibition of autophagy while activating AMPK.
Materials and Methods
Mass Spectrometry
McArdle rat hepatoma cells were exposed to adipocyte
conditioned media with or without adiponectin.16 Cell ly-
sates were digested with proteomics grade trypsin (Sigma,
St. Louis, MO) and filtered through YM-10 molecular weight
cutoff filters (Millipore, Bedford, MA). Tryptic digests were
injected into an LCQ-Deca Ion Trap mass spectrometer
coupled to a Surveyor HPLC system (Thermo Fisher Sci-
entific, Waltham, MA). The solvent, 50% methanol and
0.1% formic acid, was delivered to the spectrometer at
200 l/min. Peptide masses were acquired in positive
mode using electrospray ionization under the following
source conditions: spray voltage was 5 kV, sheath gas
was 40 (arbitrary units), auxiliary gas was 20 (arbitrary
units), and heated capillary temperature was 350 C.
Cloning of Murine SOGA
Total RNA was obtained from primary mouse hepatocytes
using Triazol reagent (Invitrogen, Carlsbad, CA). mRNA
was isolated using Oligotex mRNA Kit (Qiagen, Valencia,
CA). Primers used to clone SOGA were designed using
publicly available genomic and mRNA sequence data
based on the open reading frame of SOGA peptides we
detected by mass spectrometry. The 4.7-kb SOGA cDNA
was isolated by annealing two PCR products using overlap
extension. RNA ligasemediated RACE (Ambion, Austin, TX)
was used to clone the 5 SOGA mRNA sequence.
Antibody Production
Human- and murine-specific polyclonal antisera were
produced in three New Zealand White rabbits (Franklin
Rabbitry, NC) using a human-specific peptide antigen
STQSLTSC*FARSSRSAIRHSPSKC and two partially overlap-
ping murine-specific peptide antigens CSAQSLASCFIRPSRN
and SAQSLASC*FIRPSRNPIRHSPSKC, where C* repre-
sents acemidomethyl cysteine. Synthetic peptides were
purified by HPLC and analyzed on the LCQ-Deca Ion
Trap mass spectrometer to confirm their molecular
weight. Antigenic peptides (10 mg) were dissolved in 0.1
mol/L NaH2PO4 (pH 7.2)/0.05 mol/L NaCl and conjugated
to keyhole limpet hemocyanin (KLH; 4 mg) before injec-
tion. KLH-conjugated peptides were dissolved in 3 ml of
0.03% trifluoroacetic acid and added to 3 ml complete
Freund’s adjuvant (Sigma). New Zealand White rabbits
were injected intradermally using multiple injection sites.
After 5 weeks, each animal was reinjected subcutaneously
with KLH-conjugated antigen in 1 ml of 50% incomplete
Freund’s adjuvant (Sigma). Four weeks later, 20 ml blood
were collected and rabbits were reimmunized. Injections
and bleedings were performed at monthly intervals thereaf-
ter. The antibody production protocol was approved by
UNC’s Institutional Animal Care and Use Committee
(IACUC). Rabbit antisera recognizing human and murine
SOGA are available through Millipore (catalogue numbers
ABS81 and ABS91).
Hepatocyte Studies
Mouse livers were perfused with a Krebs-Ringer-HEPES
buffer containing collagenase IV (Sigma-Aldrich). Livers
were isolated and cells were dispersed by gentle shaking
and filtered through sterile 100 m nylon gauze. Cells
were washed twice with sterile phosphate-buffered saline
and purified by centrifugation in 50% isotonic Percoll
(Sigma-Aldrich). Cells were resuspended with Krebs-
Ringer-HEPES  Ca2 buffer to a total volume of 10 ml.
Viability was validated via trypan blue exclusion and rou-
tinely exceeded 90%. Freshly isolated mouse hepato-
cytes were plated at 105 cells per well in 12-well culture
plates coated with rat tail collagen I (BD Biosciences).
Cells were maintained in William E culture medium (In-
vitrogen), 25 mmol/L glucose and 10% horse serum (HS).
Adiponectin was provided from adipocyte-conditioned
media as previously described.16 SOGA siRNA, AICAR
(500 mol/L), or LY293004 (10 nmol/L) were introduced
to the media 48 hours before the measurement of glu-
cose production. siRNA sequences corresponding to bp
157–175 and 1812–1831 on the open reading frame of
murine SOGA were selected using a rational design al-
gorithm (Invitrogen). Transfection with a pool of 2 siRNAs
targeting SOGA had a greater knockdown efficiency than
transfecting with the individual siRNAs. Transfection was
achieved by electroporation using the Mouse Hepatocyte
Nucleofector Kit (LONZA) according to the manufactur-
er’s protocol. In brief, freshly isolated mouse hepatocytes
were diluted to 3  106 cells per tube in media without
antibiotics and centrifuged at 2000 rpm for 2 minutes.
The supernatant was removed and the cells were resus-
pended in 100 l of nucleofector solution containing 100
nmol/L of siRNA. The cell suspension was transferred to
an electroporation cuvette, which was placed in a
Nucleofector I electroporation device and pulse charge
was applied for 2 minutes using program T-28. Hepato-
cytes received 1.0 ml of media and were transferred to
12-well plates. SOGA expression and production of va-
line and glucose were assayed 48 hours after siRNA
transfection. Media was replaced with glucose-free
DMEM containing MG-132 (10 mol/L), an inhibitor of the
ubiquitin–proteasome pathway of protein degradation,
for 6–8 hours to measure hepatocytes glucose produc-
tion. Glucose was measured by colorimetric assay (Au-
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tokit Glucose CII). Valine in the medium was measured
by a UPLC (Waters) coupled TSQ-Quantum ultra triple
quad mass analyzer (ThermoFinigan) in the Biomark-
ers Facility Core at UNC. Valine was measured in se-
lected reaction monitoring mode (SRM) using the
MS/MS transition of 118372.
Late Autophagosome and Lysosome Activity
Autophagic activity was estimated by late autophago-
some and lysosome vacuole staining using Lyso Tracker
Red DND 99 (Invitrogen), a membrane permeable fluo-
rescent labeled basic amine with high affinity for the
acidic interior of late autophagosome and lysosome
vacuoles.37 Cell medium was removed and replaced with
GF/DMEM containing 50 nmol/L LysoTracker Red. Cells
were incubated for 30 minutes at 37°C, and the medium
was replaced with GF/DMEM. Digital images were ob-
tained at the Microscopy Services Laboratory of UNC with
an Olympus IX81 Motorized Inverted Microscope, a 40/
1.30 Oil DIC lens, Camera pixel count: Hamamatsu
C10600–10B 1344  1024 using the acquisition software
Volocity 5.3.2 (Perkin-Elmer). Fluorescence Filter Cubes
Specifications (Semrock, Inc.) were TXRED-4040B for rho-
damine and Texas Red: Exciter 562 nm  20, Dichroic R
530–585/T 601–800, Emitter 642  20. Lysosome and late
autophagosome vacuole number was determined from dig-
ital images as isolated punctuate staining, greater than
background staining intensity threshold, distinct from lipid
droplets in clearly demarcated cells containing 2 nuclei.
Spot recognition and enumeration according to the forego-
ing definition was determined by two individuals.
Mouse Studies
Mice were housed in ventilated isolator cage systems in
a pathogen-free barrier facility maintained at 23°C, 55%
humidity on a 12-hour light/12-hour dark cycle. Mice re-
ceived a standard chow diet consisting of 73% carbohy-
drate, 18% protein, 4% fat, and 5% ash (Purina). Young
(3–6 months old) female C57Bl/6J calorie-restricted (CR)
and ad libitum–fed (AL) mice were maintained as previ-
ously described.38 Adjustments were made to ensure
that CR mice received 70% of the ad libitum food intake.
Blood samples were collected at 1:00 PM from the tail tip
using heparinized capillary tubes (Fisher) and stored at
–20°C. Male ob/ob mice (6–9 months old; FVB back-
ground strain) received a daily dose of pioglitazone at 6
mg/kg BW in 0.025% (wt/wt) carboxymethylcellulose by
oral gavage for 4 days. Control mice received carboxym-
ethylcellulose by oral gavage for 4 days. Blood was col-
lected from the tail tip on day 5 and analyzed for glucose,
adiponectin, and 25-kDa SOGA. Immediately after the col-
lection of blood samples, ob/ob mice were sacrificed for
tissue collection by cervical dislocation. Northern blot anal-
ysis for SOGA mRNA and 18S RNA was performed using
20 g of liver RNA. NOD mice were bred and housed as
previously described.39 Where indicated, diabetic NOD
mice were injected with 5 units of insulin (NPH Human
Insulin, Isophane Suspension; 100 U/ml Novolin; Novo Nor-
disk) 24 hours before blood collection. High fat fed adi-
ponectin transgenic mice were produced as previously de-
scribed.9 Glucose was measured by colorimetric assay.
Adiponectin and SOGA were measured by SDS-PAGE
analysis using 1 l plasma. The total concentration of pro-
tein in plasma, measured by BCA assay (Pierce), did not
differ between groups. Experimental procedures were ap-
proved by IACUC.
Human Studies
Thirteen healthy women between the ages of 20–63
years and body mass indexes between 20.2 and 31.9
kg/m2 were included for this study. Inclusion was contin-
gent on a good age-typical health status, as ascertained
by physical examination and standard clinical laboratory
tests such as complete blood count, blood chemistries,
fasting glucose, insulin, lipid and liver function tests, liver
lipid content, and the presence of no known chronic
disease including diabetes. Subjects were admitted to
the Clinical and Translational Research Center of UNC
and placed on a balanced weight maintenance diet for
10 days.40 Circulating SOGA and adiponectin were mea-
sured from plasma samples collected from an intrave-
nous catheter after an overnight fast. The race–ethnicity
distribution of the participants was white (8), African
American (3), Asian (1), and Native American (1), which
reflected the local population characteristics of the Ra-
leigh-Durham-Chapel Hill area. Plasma adiponectin and
SOGA were determined by SDS-PAGE using polyclonal
antisera against human adiponectin and human SOGA,
horseradish peroxidase–linked secondary anti-rabbit
IgG. Circulating adiponectin and SOGA levels were mea-
sured by enhanced chemiluminescence (ECL) signal in-
tensity. Human studies were performed under an IRB
approved protocol (CTRC-2645; Study: 07-1158).
Statistical Analysis
Student’s t-test was used to identify significant differ-
ences when data within groups showed a normal distri-
bution and Wilcoxon-Rank Sum test was used when data
did not show a normal distribution. P values less than
0.05 were considered significant.
Results
Identification of SOGA by Mass Spectrometry
Protein extracts from adiponectin-treated hepatoma cells
were digested with trypsin and analyzed by mass spec-
trometry. Mass spectrometry revealed a peptide, KVLP-
SEEDDFLEVNSM, encoded by a gene located on chro-
mosome 2 in mice (2qH1) and chromosome 20 in
humans (20q11). Mouse liver RNA was used to clone the
full-length 4.7-kb SOGA cDNA. The GENBANK acces-
sion numbers for murine and human SOGA mRNA se-
quences are FJ977045 and BK007092, respectively. The
GENBANK accession numbers for the murine and human
SOGA gene sequences are BK007094 and BK007093,
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respectively. Northern blot analysis, using a probe rec-
ognizing the C-terminal end of SOGA, revealed a single
dominant 4–5 kb band in the liver. The open reading
frame (ORF) for SOGA mRNA predicts the production of
a 161-kDa protein that contains an internal peptide se-
quence, FKHNFLLLFMKLRWFLKRWRQG (Figure 1, A
and B). On the basis of computational algorithms that
incorporate signal peptide and cleavage site predictions,
SOGA is cleaved between G at the carboxy-terminal end
of the signal peptide and K at the beginning of the tryptic
peptide we identified by mass spectrometry.41
Function of SOGA in Primary Hepatocytes
Consistent with the predicted position of the cleavage
site, rabbit antisera recognizing the species-specific do-
main on the C-terminal region of murine SOGA recog-
nized a single 80-kDa protein in isolated hepatocytes
(Figure 2A). siRNA suppression of SOGA caused a dra-
matic increase in the number of late autophagosome and
lysosome vacuoles per cell (2.0  0.2 per cell compared
with 17.5  2.0 per cell; n  25–30 cells per group; P 
0.0001). Figure 2B shows late autophagosome and lyso-
some vacuoles by isolated punctate acidophylic fluores-
cent dye staining, which provides correlative data on
autophagy (Figure 2B).37 The hypothesis that SOGA in-
hibits autophagy is supported by the reduction of total
cell protein content 48 hours after siRNA suppression of
SOGA (11.2  0.6 g/well compared with 16.3  0.4
g/well; n  4 per group; P  0.05). Adiponectin expo-
sure caused a 36% increase of SOGA in primary hepa-
tocytes and a 50% reduction in glucose production (Fig-
ure 2C). siRNA suppression of SOGA also blocked the
inhibition of glucose production and stimulated valine
secretion (Figure 2C). The secretion of valine, an essen-
tial amino acid that cannot be metabolized, due the ab-
sence of branched chain aminotransferase in hepato-
cytes, also suggests an increase in autophagy. These
results support the hypothesis that the elevation of SOGA
in response to adiponectin exposure is linked to the
inhibition of autophagy.
Regulation of SOGA in Primary Hepatocytes
and the Correlation between Intracellular and
Extracellular Levels of SOGA
AICAR activation of AMPK caused a decrease in SOGA
that was blocked by adiponectin exposure (Figure 2D).
On the other hand, the inhibition of PI3K by LY294002
caused a decrease in SOGA that was not blocked by
adiponectin (Figure 2D). These observations suggest
that adiponectin increases SOGA through the insulin sig-
naling pathway. Consistent with the identification of an
internal signal peptide in SOGA, SDS-PAGE analysis re-
vealed that the 80-kDa SOGA fragment is secreted in he-
patocyte conditioned media. The reduction of intracellular
SOGA by AICAR and LY294002 was reflected in the levels
of SOGA in hepatocyte-conditioned media (Figure 2D).
These results suggest that extracellular levels of SOGA
could be used as a biomarker of its intracellular activity.
Circulating SOGA in Mice and Humans
Antisera from two different rabbits immunized with two
different peptide antigens, 476 and 477, detected a 25-
kDa peptide in mouse plasma (see Supplemental Figure
1A at http://ajp.amjpathol.org). Rabbit antisera recogniz-
ing murine SOGA did not cross-react with any proteins in
human plasma (see Supplemental Figure 1A at http://ajp.
amjpathol.org). Antibody detection of 25-kDa SOGA re-
quired the reduction of the sample with dithiothreitol due,
presumably, to cysteine residues within the species-spe-
cific antigenic epitope of SOGA. Based on the predicted
sequence of 25-kDa SOGA, the intramolecular disulfide
bonds between cysteine residues on the carboxy-termi-
nal end of SOGA should generate a fish hook conforma-
tion. Two observations indicate that 25-kDa SOGA circu-
lates as a monomer. First, SOGA was detected at 25 kDa
when plasma samples were reduced after SDS-PAGE.
Second, by size exclusion chromatography of plasma
proteins under native conditions, SOGA eluted at 25 kDa
(see Supplemental Figure 1B at http://ajp.amjpathol.org).
Figure 1. Predicted functional domains of SOGA. A: SOGA map showing the location of conserved ATG16 and Rab5-binding motifs, the signal peptide, and the
species-specific epitope in the predicted 161-kDa SOGA. The map also shows the predicted domains of the 80-kDa peptide detected in liver, hepatocytes, and
hepatocyte-conditioned media and the 25–kDa peptide detected in plasma. B: The amino acid sequence for murine SOGA showing the location of the Atg16
(232–375) and Rab5-binding (757–886) motifs underlined, the signal peptide (593–614) in bold, the tryptic peptide identified by mass spectrometry (703–718)
shaded, and the species specific domain (1392–1416) in a box. The position of the internal signal peptide explains why our antibodies, recognizing the
species-specific epitope near the C terminus of SOGA, detect an 80-kDa SOGA peptide rather than the 161-kDa SOGA protein.
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Figure 2. Function and regulation of SOGA in primary hepatocytes. A: Representative SDS-PAGE of primary murine hepatocyte samples showing the knockdown
of 80-kDa SOGA as a function of time after exposure to siRNA. B: Representative purified binucleate hepatocyte cultures transfected with control (left) or SOGA
siRNA (right) stained with the late autophagosome and lysosome-specific fluorescent dye LysoTracker Red. Control siRNA-transfected cultures exhibited an
average of two isolated punctate stained vacuoles per hepatocyte (indicated by green arrows), whereas SOGA siRNA-transfected cultures showed an average
of 18 stained vacuoles per hepatocyte. C: Bar graphs showing the effects of adiponectin and SOGA siRNA on glucose and valine in hepatocyte conditioned media
(top and middle) and 80-kDa SOGA in hepatocytes (bottom). Densitometry was used to determine the ECL (enhanced chemiluminescent) signal after
SDS-PAGE. D: Bar graphs showing the roles of AMPK and PI3K on adiponectin regulation of intracellular and extracellular SOGA levels. Primary hepatocytes were
incubated in the presence or absence of the 500 mol/L AICAR, a stimulator of AMPK, or 10 nmol/L LY294002, a PI3K inhibitor. Bars represent mean values 
SEM for n  4 per group where there is a significant a difference compared with control (left bar) at *P  0.05 by nonparametric Student’s t-test. Gray and black
bars indicate whether measurements were made in hepatocyte conditioned media or hepatocytes, respectively. ND indicates not detected.
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Correlation between Circulating Adiponectin
and SOGA
To further validate the link between adiponectin and
SOGA in vivo, we measured circulating levels of adi-
ponectin and SOGA in i) healthy human volunteers, ii)
wild-type mice after weight reduction by calorie restric-
tion, and iii) pioglitazone treatment in ob/ob mice, an
obese model of type II diabetes. The analysis of human
plasma from healthy fasting female volunteers (plasma
insulin: 7.1  1.0 U/ml) showed a positive correlation
between circulating levels of adiponectin and SOGA
(R2  0.82) (Figure 3A). Calorie restriction, a nutritional
intervention that doubled plasma adiponectin, resulted
in a twofold elevation of circulating SOGA (Figure 3B).
The concentration of plasma glucose in CR mice com-
pared with AL mice was 80  7 mg/dl and 131  10
mg/dl, respectively (Figure 3B). The complex oligo-
meric structure, high turnover rate, and abundance of
circulating adiponectin prevented us from using re-
combinant adiponectin to study the regulation of SOGA
in vivo.42 Therefore, oral pioglitazone treatment was
used to elevate adiponectin in ob/ob mice. Pioglita-
zone treatment caused a 40% increase of SOGA mRNA
in the liver and a threefold elevation of circulating
adiponectin and SOGA (Figure 3C). The concentration
of plasma glucose was 155  8 mg/dl in pioglitazone
treated ob/ob mice compared with 450  18 mg/dl in
untreated ob/ob mice (P  0.05) (Figure 3C). These
results support the hypothesis that adiponectin eleva-
tion of SOGA increases insulin sensitivity. Both calorie
restriction and pioglitazone treatment have pleitropic
effects beyond the elevation of circulating adiponectin,
making it difficult to draw any direct conclusions about
the linkage between adiponectin and SOGA. Hence,
we compared circulating levels of SOGA between wild-
Figure 3. Circulating adiponectin and SOGA
levels in humans and mice. A: Adiponectin and
25-kDa SOGA levels in human plasma from
healthy female volunteers (ages 20–63; n  13).
Plasma was collected after an overnight fast.
Values represent averages from two plasma sam-
ples taken 10 minutes apart. A correlation coef-
ficient (R2) of 0.82 was found between SOGA
and adiponectin. B: The effect of AL versus 30%
CR feeding on adiponectin, SOGA, and glucose
in female wild-type mice. Bar graphs show lev-
els of plasma adiponectin (top), 25-kDa SOGA
(middle), and glucose (bottom). C: The effect
of pioglitazone treatment on liver SOGA mRNA
and circulating adiponectin, SOGA, and glucose
in diabetic ob/ob mice. Mice received a daily
dose of pioglitazone (TZD) or placebo (CTL) by
oral gavage. Bar graphs show the levels of
plasma adiponectin (top), liver SOGA mRNA/
18S RNA (second), plasma 25 kDa SOGA
(third), and plasma glucose (bottom) after 4
days of treatment. D: Circulating levels of adi-
ponectin and SOGA in male adiponectin trans-
genic mice and their wild-type littermates on a
high-fat diet. Bars in panels B, C, and D repre-
sent mean  SEM for n  4–5 per group where
there is a significant difference (*P  0.05) by
nonparametric Student’s t-test.
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type and adiponectin transgenic mice (Figure 3D). Pre-
vious studies have shown that the threefold elevation of
adiponectin in transgenic mice exerts a protective ef-
fect against a diabetogenic high-fat diet.9,16 Consistent
with a stimulatory effect of adiponectin, circulating lev-
els of SOGA were higher in adiponectin transgenic
mice than their wild-type littermates on a high-fat diet
(Figure 3D). These results further support the hypoth-
esis that an increase in SOGA contributes to the re-
duction of plasma glucose.
Correlation between Circulating Insulin and
SOGA
Because adiponectin is an insulin sensitizer and the in-
hibition of the insulin signaling intermediate PI3K blocked
the induction of SOGA in isolated hepatocytes (Figure
2D), we sought to determine whether there is a correla-
tion between circulating levels of insulin and SOGA dur-
ing i) feeding and fasting in humans and ii) insulin with-
drawal in NOD mice, a model of type I diabetes.
Consistent with the hypothesis that insulin stimulates
SOGA, a 12-hour fast in healthy human volunteers was
associated with a 25% reduction in circulating SOGA
(Figure 4A). A threefold reduction of circulating SOGA in
hyperglycemic NOD mice, in comparison with euglyce-
mic NOD mice, also suggests that insulin induces SOGA
in vivo (Figure 4B). In support of the hypothesis that an
increase of SOGA contributes to the reduction of plasma
glucose, the treatment of type I diabetes in NOD mice by
insulin injection was associated with a twofold induction
of SOGA (Figure 4B). The reduction of SOGA during
fasting and insulin withdrawal is consistent with the in-
crease of autophagy in these states.21–23
Discussion
The results of this study suggest that the elevation of
SOGA in response to adiponectin and insulin lowers liver
glucose production through the inhibition of autophagy,
resulting in a decrease of plasma glucose. The observa-
tion that knockdown of SOGA elevated glucose produc-
tion in primary hepatocytes indicates that SOGA is an
inhibitor of glucose production. The elevation of glu-
cose production during knockdown of SOGA was
linked to changes in primary hepatocytes, which sug-
gested an increase in autophagy. The reduction in
protein content, increased staining of late autophago-
some and lysome vacuoles, and the secretion of valine
are all indicative of increased autophagy during the
knockdown of SOGA.
The mechanism through which SOGA interferes with
autophagy may be linked to the Atg16- and Rab5-binding
motifs in SOGA.36 Both Atg16 and Rab5 contribute to the
early stages of autophagy.43 Although Atg16 is an essen-
tial component of the autophagic machinery, adenoviral
overexpression of Atg16 inhibits autophagy in mamma-
lian cells.44,45 The disruption of autophagy by overex-
pression of Atg16 provides a paradigm that may explain
how elevated SOGA inhibits autophagy. Although the
current study focuses on the role of SOGA in the liver, it
is important to point out that SOGA is expressed in the
other gluconeogenic organs such as the kidneys. SOGA
is also expressed in tissues that are rich sources of
gluconeogenic substrates like skeletal and cardiac
muscle. Therefore, the elevation of SOGA in extrahe-
patic tissues can play a critical role in the reduction of
glucose production and the amelioration of glucose
homeostasis.
Intracellular levels of SOGA in isolated hepatocytes were
proportional to the levels of SOGA in hepatocyte-condi-
tioned media, leading us to propose that circulating levels
Figure 4. Circulating levels of SOGA in relation
to insulin in humans and mice. A: Percent
change in circulating levels of SOGA in healthy
human volunteers (20–43 years old) measured
at 8:00–11:00 AM, either at two hours after feed-
ing or following an overnight (10–12 hour) fast.
Bars represent mean values  SEM for n  5,
and there is a significant a difference at *P 0.05
by nonparametric Student’s t-test. B: The effect
of insulin withdrawal and insulin injection on
SOGA and glucose in female NOD mice. Circu-
lating levels of 25-kDa SOGA and glucose in
NOD mice without diabetes (Group 1), NOD
mice with diabetes (Group 2), and NOD mice
with diabetes treated by a single injection of
insulin 24 hours earlier (Group 3). Bar graphs
show the levels of plasma SOGA (top) and glu-
cose (bottom). Bars show mean  SEM for n 
5 per group. Statistical significance was deter-
mined by Student’s t-test where *P  0.05.
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of SOGA can be used as a biomarker for the intracellular
levels of SOGA. This hypothesis was supported by the
elevation of liver SOGA mRNA and circulating SOGA in
pioglitazone-treated ob/ob mice. Our in vitro experiments
suggest that the elevation of circulating SOGA indicates a
decrease in glucose production. This interpretation is con-
sistent with the elevation of circulating SOGA after calorie
restriction, oral pioglitazone, transgenic elevation of adi-
ponectin, feeding, and insulin injection. Although in vivo
glucose production was not measured in the present study,
previous reports show that glucose production is reduced
by the elevation of adiponectin in transgenic mice, the im-
plementation of calorie restriction, the treatment of type II
diabetes by oral insulin sensitizers, and the treatment of
type I diabetes by insulin.6,8,9,16,46,47
The elevation of SOGA in CR, pioglitazone-treated
and adiponectin-transgenic mice supports the hypoth-
esis that adiponectin induces SOGA in vivo. In isolated
hepatocytes, the elevation of SOGA in response to
adiponectin was not impaired by AMPK. However, adi-
ponectin-mediated increases in SOGA were impaired by
pharmacological inhibition of the insulin-signaling inter-
mediate PI3K, suggesting that adiponectin regulation of
SOGA is mediated through the insulin-signaling pathway.
The elevation of circulating SOGA by feeding calorie
restriction, pioglitazone treatment and insulin injection
support the hypothesis that SOGA is induced through the
insulin-signaling pathway. Adiponectin could increase
SOGA through the insulin-signaling pathway via APPL1,
an adaptor protein that binds to the intracellular domain
of the adiponectin receptors and the catalytic subunit of
PI3K.15,48,49
Antibodies recognizing the C-terminal region of murine
SOGA show that cultured hepatocytes as well as liver
samples incubated ex vivo secrete an 80-kDa SOGA frag-
ment rather than a 161-kDa protein predicted by the
4.7-kb cDNA. The size discrepancy is explained by the
location of an internal signal peptide; an internal signal
peptide is also observed in chicken ovalbumin.50 The
fate and function of the amino-terminal portion of SOGA is
unknown to us because our antibodies only recognize the
carboxy-terminal end of SOGA. The presence of re-
peated LXXXXXXL sequences in the amino-terminal
portion of SOGA (16–30 and 230–262) suggests a
potential feedback mechanism through protein–protein
interactions of leucine zipper motifs in SOGA and
APPL1.48 The absence of 25-kDa SOGA in hepatocytes
and liver-conditioned media suggests that proteolytic
cleavage of 80-kDa SOGA depends on an extracellular
factor that is inactive or absent in vitro. The mechanism
that yields the 25-kDa SOGA fragment is currently
unknown. The incubation of mouse hepatocyte–condi-
tioned media containing 80-kDa SOGA with endothelial
cells (HUVECs) or human plasma did not yield a 25-
kDa fragment. Circulating SOGA may play a physio-
logical role in glucose homeostasis. The function of
circulating SOGA will emerge from ongoing studies
with recombinant SOGA.
The discovery that circulating levels of adiponectin
and SOGA are highly correlated in humans suggests
that the measurement of SOGA may be clinically rele-
vant. For example, while glitazone drug treatment is
almost always effective in the induction of adiponectin,
it is only effective in lowering glucose in 70% of type II
diabetics.51 Insulin treatment of type I diabetes is also
not completely effective 100% of the time. Based on
the results presented here, it would not be surprising if
poor clinical outcomes were associated with low induc-
tion of SOGA.
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